Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of RPL554 in Healthy and COPD Subjects
NCT02307162Phase 1Completed
- Sponsor
- Verona Pharma
- Start
- Dec 2014
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing RPL554 with Placebo (2 arms). Primary endpoints: Adverse events, Vital signs and 4 more. Started Dec 2014; status: completed.
02
Drugs
ensifentrine
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02307162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02307162.